
Jeremy Skillington, Poolbeg Pharma CEO summarises POLB 001 benefits for cancer immunotherapy
Description
#POLB #Jeremy Skillington #Poolbeg #Oncology #Immunotherapy #InvestorSummit #AIM Aim-listed Poolbeg Pharma #POLB pulled together an authoritative panel to discuss the outlook for a significant pharma sector – cancer immunotherapy. Poolbeg CEO Jeremy Skillington was joined at the Investor Summit by Dr Martin Kaiser, Professor of Haematology, and Consultant Haemato-Oncologist at the Institute of Cancer Research/Royal Marsden Hospital, and Dr Brian White, an experienced healthcare analyst from Shore Capital. Copia’s Donald Leggatt caught up with Jeremy after the panel discussion and began the interview by asking him to put cancer immunotherapy treatment in context. View the full panel discussion here: https://youtu.be/T_P0NDVx5BM